Ozempic, a drug initially developed for type 2 diabetes management, has garnered significant attention for its unexpected weight loss side effect. Semaglutide, the active ingredient in Ozempic, was approved by the FDA in 2017. During pre-approval studies, a notable side effect was observed: patients were losing weight. This has led to an increased demand for the drug, posing challenges for those with diabetes to access it.

The medication belongs to a class called GLP-1 (glucagon-like peptide 1) receptor analogs and is administered as a weekly injection. It mimics a hormone naturally produced in the small intestine, aiding in various bodily functions, including blood sugar regulation.

Ozempic works by binding to receptors in the brain related to satiety, increasing the feeling of fullness and reducing overall food and calorie consumption. It also slows down digestion, impacting the body’s overall response to food intake. For instance, certain foods, like cruciferous vegetables and garlic, can alter body odor due to the release of sulfur-like compounds during digestion.

Interestingly, Ozempic is not officially approved for weight loss; that distinction goes to a similar medication named Wegovy, which contains a higher dose of semaglutide. It’s important to note that the body may adapt to these drugs, potentially establishing a new normal for weight, which can affect long-term weight management.

While Ozempic’s primary use is for controlling blood sugar in adults with diabetes, its impact on weight loss has led to a broader discussion among healthcare providers and patients alike. This raises questions about the ethical implications of prescribing a diabetes medication for weight loss, especially considering the drug’s rising popularity and its resulting scarcity for those who need it for its intended purpose.

For more detailed information on Ozempic and its effects, visit WUSF Health, USC Internal Medicine, Harvard Health, Harvard Health Blog, Northwell Health, UC Davis Health, and Cornell University Blog for further insights.